Compare TGLS & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGLS | TLX |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | Colombia | Australia |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 3.3B |
| IPO Year | 2012 | N/A |
| Metric | TGLS | TLX |
|---|---|---|
| Price | $52.80 | $6.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $80.00 | $21.00 |
| AVG Volume (30 Days) | ★ 283.8K | 178.9K |
| Earning Date | 02-26-2026 | 01-19-2026 |
| Dividend Yield | ★ 1.15% | N/A |
| EPS Growth | ★ 20.09 | N/A |
| EPS | ★ 3.84 | 0.04 |
| Revenue | ★ $977,886,000.00 | $664,225,558.00 |
| Revenue This Year | $12.04 | N/A |
| Revenue Next Year | $10.69 | N/A |
| P/E Ratio | ★ $13.57 | $150.68 |
| Revenue Growth | 15.70 | ★ 55.35 |
| 52 Week Low | $44.26 | $6.40 |
| 52 Week High | $90.34 | $30.36 |
| Indicator | TGLS | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 54.64 | 32.43 |
| Support Level | $51.81 | $6.94 |
| Resistance Level | $53.60 | $7.43 |
| Average True Range (ATR) | 1.66 | 0.24 |
| MACD | 0.30 | -0.07 |
| Stochastic Oscillator | 66.18 | 2.66 |
Tecnoglass Inc is a manufacturer of hi-spec architectural glass and windows for residential and commercial construction industries, operating through its direct and indirect subsidiaries. Its product offerings include tempered glass, laminated glass, thermo-acoustic glass, sliding windows, projecting windows, guillotine windows, sliding doors, loating facades, automatic doors, bathroom dividers, and commercial display windows, among others. The company has one operating segment, Architectural Glass and Windows, which is also its reporting segment. Geographically, the company generates maximum revenue from its customers in the United States, followed by Colombia, Panama, and other regions.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.